drugset / Trial / NCT04456049
Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-1
Phase 2
Terminated
7 enrolled
Ricardo Pereira Mestre
Institute for Research in Biomedicine · collabInstitute of Oncology Research · collabOncology Institute of Southern Switzerland · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
High risk outpatient adult males with a confirmed SARS-CoV-2 infection will be included in the study. Patients will be randomized to receive Enzalutamide with standard of care (SOC) or SOC alone. Enzalutamide will be administered daily p.o. from Day 1 to Day 28 or until confirmed negativization of Nasopharyngeal swap (NPS) Polymerase chain reaction (PCR) (2 consecutive negative samples), whichever occurs first.
Timeline
- Start
- 2020-08-24
- Primary completion
- 2021-06-09
- Completion
- 2021-06-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 40 mg | Oral |